<!doctype html><html lang=cn><head><meta charset=utf-8><meta http-equiv=x-ua-compatible content="IE=edge"><meta name=viewport content="width=device-width,initial-scale=1"><meta name=referrer content="no-referrer"><link rel=dns-prefetch href=https://i.geekbank.cf/><title>CROI2020：HIV新型治疗药物研究进展荟萃，长效抑制剂效果喜人 | 极客快訊</title><meta property="og:title" content="CROI2020：HIV新型治疗药物研究进展荟萃，长效抑制剂效果喜人 - 极客快訊"><meta property="og:type" content="article"><meta property="og:locale" content="cn"><meta property="og:image" content="https://p1.pstatp.com/large/pgc-image/6137946c0af04abb945d29d1abdb1c17"><link rel=alternate hreflang=x-default href=https://geekbank.cf/tw/%e7%a7%91%e6%8a%80/dda5dfa.html><link rel=alternate hreflang=zh-tw href=https://geekbank.cf/tw/%e7%a7%91%e6%8a%80/dda5dfa.html><link rel=alternate hreflang=zh-cn href=https://geekbank.cf/cn/%e7%a7%91%e6%8a%80/dda5dfa.html><link rel=alternate hreflang=zh-hk href=https://geekbank.cf/tw/%e7%a7%91%e6%8a%80/dda5dfa.html><link rel=alternate hreflang=zh-mo href=https://geekbank.cf/tw/%e7%a7%91%e6%8a%80/dda5dfa.html><link rel=alternate hreflang=zh-my href=https://geekbank.cf/cn/%e7%a7%91%e6%8a%80/dda5dfa.html><link rel=alternate hreflang=zh-sg href=https://geekbank.cf/cn/%e7%a7%91%e6%8a%80/dda5dfa.html><link rel=canonical href=https://geekbank.cf/tw/%e7%a7%91%e6%8a%80/dda5dfa.html><meta property="article:published_time" content="2020-10-29T20:50:51+08:00"><meta property="article:modified_time" content="2020-10-29T20:50:51+08:00"><meta name=Keywords content><meta name=description content="CROI2020：HIV新型治疗药物研究进展荟萃，长效抑制剂效果喜人"><meta name=author content="极客快訊"><meta property="og:url" content="/cn/%E7%A7%91%E6%8A%80/dda5dfa.html"><link rel=apple-touch-icon sizes=180x180 href=../../apple-touch-icon.png><link rel=icon type=image/png sizes=32x32 href=../../favicon-32x32.png><link rel=icon type=image/png sizes=16x16 href=../../favicon-16x16.png><link rel=manifest href=../../site.webmanifest><link rel=mask-icon href=../../safari-pinned-tab.svg color=#5bbad5><meta name=msapplication-TileColor content="#ffc40d"><meta name=theme-color content="#ffffff"><link rel=stylesheet href=https://geekbank.cf/css/normalize.css><link rel=stylesheet href=https://geekbank.cf/css/style.css><script type=text/javascript src=https://cdnjs.cloudflare.com/ajax/libs/jquery/3.4.1/jquery.min.js></script><script type=text/javascript src=https://geekbank.cf/js/jqthumb.min.js></script><script data-ad-client=ca-pub-3525055026201463 async src=https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js></script></head><body><header id=header class=clearfix><div class=container><div class=col-group><div class=site-name><h1><a id=logo href>🤓 极客快讯 Geek Bank</a></h1><p class=description>为你带来最全的科技知识 🧡</p></div><div><nav id=nav-menu class=clearfix><a class=current href>猜你喜歡</a>
<a href=../../tw/categories/%E7%A7%91%E6%8A%80.html title=科技>科技</a>
<a href=../../tw/categories/%E9%81%8A%E6%88%B2.html title=遊戲>遊戲</a>
<a href=../../tw/categories/%E7%A7%91%E5%AD%B8.html title=科學>科學</a></nav></div></div></div></header><div id=body><div class=container><div class=col-group><div class=col-8 id=main><div class=res-cons><article class=post><header><h1 class=post-title>CROI2020：HIV新型治疗药物研究进展荟萃，长效抑制剂效果喜人</h1></header><date class="post-meta meta-date">2020-10-29</date><div class=post-meta><span>|</span>
<span class=meta-category><a href=cn/categories/%E7%A7%91%E6%8A%80.html>科技</a></span></div><div class=post-content><p>此文章来源于拉米Dr，作者是拉米医生</p><p>2020年3月8-11日，原计划在波士顿召开的本年度的CROI大会改用网络会议的形式如期召开，这次会议上又有哪些研究进展，一起跟着拉米医生来看看吧。</p><div class=pgc-img><img alt=CROI2020：HIV新型治疗药物研究进展荟萃，长效抑制剂效果喜人 onerror=errorimg.call(this); src=https://p1.pstatp.com/large/pgc-image/6137946c0af04abb945d29d1abdb1c17><div class=pgc-img-handler><div class="pgc-img-button editorImage fix-android"><section></section></div><div class="pgc-img-button setImageCover fix-android"><section></section></div><div class="pgc-img-button deleteImage fix-android"><section></section></div></div><div class=pgc-img-border></div></div><p><br></p><div class=pgc-img><img alt=CROI2020：HIV新型治疗药物研究进展荟萃，长效抑制剂效果喜人 onerror=errorimg.call(this); src=https://p1.pstatp.com/large/pgc-image/c8d94dfd08e34d1bb6c5d5197443a1e4><div class=pgc-img-handler><div class="pgc-img-button editorImage fix-android"><section></section></div><div class="pgc-img-button setImageCover fix-android"><section></section></div><div class="pgc-img-button deleteImage fix-android"><section></section></div></div><div class=pgc-img-border></div></div><p><br></p><p>点击图片可跳转至CROI官网</p><p><strong>1</strong></p><div class=pgc-img><img alt=CROI2020：HIV新型治疗药物研究进展荟萃，长效抑制剂效果喜人 onerror=errorimg.call(this); src=https://p1.pstatp.com/large/pgc-image/f2d88441992c4f8b8f8c6f9ab1069f14><div class=pgc-img-handler><div class="pgc-img-button editorImage fix-android"><section></section></div><div class="pgc-img-button setImageCover fix-android"><section></section></div><div class="pgc-img-button deleteImage fix-android"><section></section></div></div><div class=pgc-img-border></div></div><p><br></p><p><strong>药物传递技术实现体内持续HIV抗体的产生</strong></p><div class=pgc-img><img alt=CROI2020：HIV新型治疗药物研究进展荟萃，长效抑制剂效果喜人 onerror=errorimg.call(this); src=https://p9.pstatp.com/large/pgc-image/593a27a0acf24e8ab612d87894842b46><div class=pgc-img-handler><div class="pgc-img-button editorImage fix-android"><section></section></div><div class="pgc-img-button setImageCover fix-android"><section></section></div><div class="pgc-img-button deleteImage fix-android"><section></section></div></div><div class=pgc-img-border></div></div><p><br></p><p>美国国立卫生研究院（NIH）过敏和传染病研究所（NIAID）在本次会议上公布了一种针对HIV-1包膜糖蛋白CD4结合位点的广泛中和抗体（bNAb）的I期、开放性剂量递增试验现阶段的结果。</p><p>NIAID的科学家们开发了一种药物传递系统（drug-delivery system），通过对人体无害的腺相关病毒（AAV8）将基因传递到体细胞中，并在长时间在体内产生抗体。目前，利用该方法在动物模型中传递猴免疫缺陷病毒（SIV），能成功在猴子体内安全地产生较高水平的SIV抗体，防止它们感染SIV。</p><div class=pgc-img><img alt=CROI2020：HIV新型治疗药物研究进展荟萃，长效抑制剂效果喜人 onerror=errorimg.call(this); src=https://p1.pstatp.com/large/pgc-image/1646b82234bb4d08abaa530d47707e1c><div class=pgc-img-handler><div class="pgc-img-button editorImage fix-android"><section></section></div><div class="pgc-img-button setImageCover fix-android"><section></section></div><div class="pgc-img-button deleteImage fix-android"><section></section></div></div><div class=pgc-img-border></div></div><p><br></p><p>腺相关病毒载体基因结构</p><p>本次研究选用的VRC07是一种广泛中和抗体，在实验室条件下，能阻止大部分的HIV菌株感染人体细胞。目前该研究公布了正在接受试验的前八名参与者的初步结果，这些参与者分成三组接受一次不同剂量水平的AAV8-VRC07肌肉注射，并继续接受抗逆转录病毒治疗。</p><div class=pgc-img><img alt=CROI2020：HIV新型治疗药物研究进展荟萃，长效抑制剂效果喜人 onerror=errorimg.call(this); src=https://p1.pstatp.com/large/pgc-image/6d0edf1184694704bbf757aab41b2777><div class=pgc-img-handler><div class="pgc-img-button editorImage fix-android"><section></section></div><div class="pgc-img-button setImageCover fix-android"><section></section></div><div class="pgc-img-button deleteImage fix-android"><section></section></div></div><div class=pgc-img-border></div></div><p><br></p><p>受试者体内VRC07的浓度</p><p>在注射了AAV8-VRC07之后，所有受试者血液中都能检测到VRC07，其产量在注射后4-6周达到早期高峰，随后下降，并在16周后缓慢地再次增加，其中低剂量和中剂量组的5个受试者中的3个在注射一年后体内抗体水平高于4-6周时的水平。</p><p><strong>2</strong></p><div class=pgc-img><img alt=CROI2020：HIV新型治疗药物研究进展荟萃，长效抑制剂效果喜人 onerror=errorimg.call(this); src=https://p9.pstatp.com/large/pgc-image/5e52f295c1b14275aed40ec6bfa170d6><div class=pgc-img-handler><div class="pgc-img-button editorImage fix-android"><section></section></div><div class="pgc-img-button setImageCover fix-android"><section></section></div><div class="pgc-img-button deleteImage fix-android"><section></section></div></div><div class=pgc-img-border></div></div><p><br></p><p><strong>ViiV：长效抑制剂效果喜人</strong></p><div class=pgc-img><img alt=CROI2020：HIV新型治疗药物研究进展荟萃，长效抑制剂效果喜人 onerror=errorimg.call(this); src=https://p3.pstatp.com/large/pgc-image/fd44a50d1da243adb86d2c354aac98d4><div class=pgc-img-handler><div class="pgc-img-button editorImage fix-android"><section></section></div><div class="pgc-img-button setImageCover fix-android"><section></section></div><div class="pgc-img-button deleteImage fix-android"><section></section></div></div><div class=pgc-img-border></div></div><p><br></p><p>ViiV Healthcare也在本次会议上公布了关于长效肌注疗法CABOTEGRAVIR + RILPIVIRINE（CAB+RPV）的3期随机，多中心，平行，非劣效性，开放性试验FLAIR 96周的以及多中心、开放性、3b期非劣效性试验ATLAS-2M的结果。</p><p>1.</p><p><strong>FLAIR：CAB+RPV非劣效于口服三药</strong></p><div class=pgc-img><img alt=CROI2020：HIV新型治疗药物研究进展荟萃，长效抑制剂效果喜人 onerror=errorimg.call(this); src=https://p1.pstatp.com/large/pgc-image/3fa2a9b5918745f2bad1c41494a0ec89><div class=pgc-img-handler><div class="pgc-img-button editorImage fix-android"><section></section></div><div class="pgc-img-button setImageCover fix-android"><section></section></div><div class="pgc-img-button deleteImage fix-android"><section></section></div></div><div class=pgc-img-border></div></div><p><br></p><p>FLAIR试验设计</p><p>此前公布的LATTE-2试验48周结果表明，每4或8周给予CAB+RPV LA（long-acting）可维持HIV-1 RNA＜50c/mL大于三年。在病毒抑制方面，CBA+RPV 被证实非劣效于三药口服疗法（DTG/ABC/3TC）。</p><div class=pgc-img><img alt=CROI2020：HIV新型治疗药物研究进展荟萃，长效抑制剂效果喜人 onerror=errorimg.call(this); src=https://p9.pstatp.com/large/pgc-image/3541b12ccb6b495a8ed321cc85f0c7db><div class=pgc-img-handler><div class="pgc-img-button editorImage fix-android"><section></section></div><div class="pgc-img-button setImageCover fix-android"><section></section></div><div class="pgc-img-button deleteImage fix-android"><section></section></div></div><div class=pgc-img-border></div></div><p><br></p><p>48周（上）和96周（下）病毒学结果</p><p>在本次会议公布的数据中，在96周，每月一次CAB+RPV LA疗效非劣效于继续口服DTG/ABC/3TC（86.6% vs. 89.4% ），与48周结果相符。且该方案耐受性好，在48周后没有新的不良事件，总体满意度高。</p><p>2.</p><p><strong>ATLAS-2M：2月一次疗效依然显著</strong></p><p>ATLAS-2M试验将受试者随机分成不同剂量的Q8W组（2月一次， CAB 600mg+RPV 900mg）和Q4W组（每月一次， CAB 400mg+RPV 600mg）。</p><div class=pgc-img><img alt=CROI2020：HIV新型治疗药物研究进展荟萃，长效抑制剂效果喜人 onerror=errorimg.call(this); src=https://p3.pstatp.com/large/pgc-image/a73b848359254d56ac723467261f5e2e><div class=pgc-img-handler><div class="pgc-img-button editorImage fix-android"><section></section></div><div class="pgc-img-button setImageCover fix-android"><section></section></div><div class="pgc-img-button deleteImage fix-android"><section></section></div></div><div class=pgc-img-border></div></div><p><br></p><p>ATLAS-2M试验设计</p><p>48周结果显示，Q8W组给药效果显著，不低于Q4W组，病毒抑制率分别为94.3% vs. 93.5%，病毒学失败率低（1%），耐受性好，Q8W组受试者接受度更高，表明2月一次CAB+RPV LA疗法是一种创新且有效的疗法。</p><div class=pgc-img><img alt=CROI2020：HIV新型治疗药物研究进展荟萃，长效抑制剂效果喜人 onerror=errorimg.call(this); src=https://p1.pstatp.com/large/pgc-image/6d6259dec6ae401f88e79c5eddb5a3a5><div class=pgc-img-handler><div class="pgc-img-button editorImage fix-android"><section></section></div><div class="pgc-img-button setImageCover fix-android"><section></section></div><div class="pgc-img-button deleteImage fix-android"><section></section></div></div><div class=pgc-img-border></div></div><p><br></p><p>ATLAS-2M实验结果</p><p><strong>3</strong></p><div class=pgc-img><img alt=CROI2020：HIV新型治疗药物研究进展荟萃，长效抑制剂效果喜人 onerror=errorimg.call(this); src=https://p3.pstatp.com/large/pgc-image/69b71becaefc4b998d36b210337c27c7><div class=pgc-img-handler><div class="pgc-img-button editorImage fix-android"><section></section></div><div class="pgc-img-button setImageCover fix-android"><section></section></div><div class="pgc-img-button deleteImage fix-android"><section></section></div></div><div class=pgc-img-border></div></div><p><br></p><p><strong>Gilead：在研新药GS-6207研究</strong></p><div class=pgc-img><img alt=CROI2020：HIV新型治疗药物研究进展荟萃，长效抑制剂效果喜人 onerror=errorimg.call(this); src=https://p1.pstatp.com/large/pgc-image/d4f325f6f7c04c5fb6ce06b69aa1c34b><div class=pgc-img-handler><div class="pgc-img-button editorImage fix-android"><section></section></div><div class="pgc-img-button setImageCover fix-android"><section></section></div><div class="pgc-img-button deleteImage fix-android"><section></section></div></div><div class=pgc-img-border></div></div><p><br></p><p>吉利德科学公司在会上发布了新药GS-6207 1b阶段的临床和临床前期数据，探索GS-6207的用途。GS-6207是一种创新性的HIV-1衣壳功能抑制剂，能够抑制病毒复制过程中多种衣壳依赖性的重要功能，具有成为每3个月或更长时间一次的皮下长效药物的潜力。</p><div class=pgc-img><img alt=CROI2020：HIV新型治疗药物研究进展荟萃，长效抑制剂效果喜人 onerror=errorimg.call(this); src=https://p3.pstatp.com/large/pgc-image/48f7b92a1499414fadb391339990724e><div class=pgc-img-handler><div class="pgc-img-button editorImage fix-android"><section></section></div><div class="pgc-img-button setImageCover fix-android"><section></section></div><div class="pgc-img-button deleteImage fix-android"><section></section></div></div><div class=pgc-img-border></div></div><p><br></p><p>GS-6207作用模式图</p><div class=pgc-img><img alt=CROI2020：HIV新型治疗药物研究进展荟萃，长效抑制剂效果喜人 onerror=errorimg.call(this); src=https://p9.pstatp.com/large/pgc-image/7e29db941e854e5091094d7662788526><div class=pgc-img-handler><div class="pgc-img-button editorImage fix-android"><section></section></div><div class="pgc-img-button setImageCover fix-android"><section></section></div><div class="pgc-img-button deleteImage fix-android"><section></section></div></div><div class=pgc-img-border></div></div><p><br></p><p>实验设计</p><p>到第10天，所有受试者的HIV-1 RNA水平平均降低≥1.8 log10 c/mL，单次皮下剂量的的gs-6207即可产生有效的抗病毒活性，使HIV-1 RNA下降平均1.4-2.3log10c/ml。预计平均浓度≥4.4ng/mL即可提供最大的抗病毒活性。目前该药还有2个正在PLWH对象中进行中的临床试验，现有结果支持GS-6207作为长效抗逆转录病毒药物进行进一步的临床评价。</p><div class=pgc-img><img alt=CROI2020：HIV新型治疗药物研究进展荟萃，长效抑制剂效果喜人 onerror=errorimg.call(this); src=https://p1.pstatp.com/large/pgc-image/2352c2248ee945dea933c49e8e705c5b><div class=pgc-img-handler><div class="pgc-img-button editorImage fix-android"><section></section></div><div class="pgc-img-button setImageCover fix-android"><section></section></div><div class="pgc-img-button deleteImage fix-android"><section></section></div></div><div class=pgc-img-border></div></div><p><br></p><p>抗病毒活性</p><p><strong>结语</strong></p><p>现阶段大部分HIV感染者都能通过鸡尾酒疗法，通过三种不同的药物搭配控制体内的病毒载量，但“每天一把药”对于A宝而言仍然是一种很大的负担，漏服、隐私等问题困扰着许多人。现在，简化治疗、长效疗法等研究越来越倾向于减轻患者的药物负担，让HIV治疗变得简便易行。我们期望这些新药能在接下来的临床试验中表现出色，能够尽快应用到临床，造福广大A宝。</p></div><div class="post-meta meta-tags"><ul class=clearfix><li><a>'CROI2020','HIV','治疗'</a></li></ul></div></article></div></div><div id=secondary><section class=widget><form id=search action=//www.google.com/search method=get accept-charset=utf-8 target=_blank _lpchecked=1><input type=text name=q maxlength=20 placeholder=搜索>
<input type=hidden name=sitesearch value=geekbank.cf>
<button type=submit>🔍</button></form></section><section class=widget><h3 class=widget-title>最新文章 ⚡</h3><ul class=widget-list></ul></section><section class=widget><h3 class=widget-title>其他</h3><ul class=widget-list><li><a href=TOS.html>使用條款</a></li><li><a href=CommentPolicy.html>留言政策</a></li><li><a href=mailto:gdnews@tuta.io rel=nofollow>DMCA</a></li><li><a href=mailto:gdnews@tuta.io rel=nofollow>聯絡我們</a></li></ul></section></div></div></div></div><footer id=footer><div class=container>&copy; 2020 <a href>极客快訊</a></div></footer><script type=text/javascript>window.MathJax={tex2jax:{inlineMath:[['$','$']],processEscapes:true}};</script><script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.5/MathJax.js?config=TeX-MML-AM_CHTML" async></script><a id=rocket href=#top></a><script type=text/javascript src=https://kknews.cf/js/totop.js async></script><script type=application/javascript>var doNotTrack=false;if(!doNotTrack){window.ga=window.ga||function(){(ga.q=ga.q||[]).push(arguments)};ga.l=+new Date;ga('create','UA-146415161-2','auto');ga('send','pageview');}</script><script async src=https://www.google-analytics.com/analytics.js></script><script type=text/javascript src="//s7.addthis.com/js/300/addthis_widget.js#pubid=ra-5e508ed9e4e698bb"></script></body></html>